TABLE 1: Baseline demographic and hemodynamic clinical characteristics of the study groups.
| General features | PAH-Sch | non-Sch PAH | Total | p* value |
|---|---|---|---|---|
| N† | N† | N | ||
| Age (years)* | 56 (46 ± 13) | 42 (42 ± 15) | 98 (45 ± 14) | 0.172 |
| Gender † | ||||
| Male | 20 (35.7%) | 10 (23.8%) | 30 (30.6%) | |
| Female | 36 (64.3%) | 32 (76.2%) | 68 (69.4%) | 0.206 |
| Functional class † | ||||
| I | 03 (5.4%) | 01 (2.4%) | 04 (4.1%) | |
| II | 17 (30.4%) | 8 (19.0%) | 25 (25.5%) | |
| III | 16 (28.6%) | 16 (38.1%) | 32 (32.7%) | |
| IV | 20 (35.7%) | 17 (40.5%) | 37 (37.8%) | 0.490 |
| Echocardiogram (PASP, mmHg)* | 56 (97.28 ± 27.23) | 41 (88.76 ± 21.80) | 97 (93.68 ± 25.31) | 0.102 |
| 6MWT (m)* | 56 (241.70 ± 126.70) | 42 (211.10 ± 122.91) | 98 (228.58 ± 125.38) | 0.234 |
| NT-ProBNP* (pg/mL) | 43 (1444.23 ± 2202.45) | 24 (2528.27 ± 2720.45) | 67 (1832.54 ± 2437.25) | 0.081 |
| MPAP (mmHg)* | 56 (60.80 ± 16.26) | 42 (57.07 ± 19.58) | 98 (59.20 ± 17.25) | 0.291 |
| MPRA (mmHg)* | 56 (13.11 ± 5.98) | 42 (13.57 ± 7.34) | 98 (13.31 ±6.56) | 0.731 |
| PVR (U Wood)* | 56 (48.31 ± 22.10) | 42 (45.39 ± 29.70) | 98 (2.58 ± 1.16) | 0.578 |
| CI (L/min/m²)* | 56 (2.53 ± 1.15) | 42 (2.65 ± 1.20) | 98 (2.58 ± 1.16) | 0.608 |
| S pa O 2 * | 56 (58.88 ± 13.67) | 42 (63.14 ± 11.13) | 98(60.70 ± 12.76) | 0.102 |
PAH-Sch: schistosomal pulmonary arterial hypertension; non-Sch PAH: non-schistosomal pulmonary arterial hypertension; PASP: pulmonary artery systolic pressure; 6MWT: 6-minute walk test; NT-proBNP: N-terminal-pro B-type natriuretic peptide; MPAP: mean pulmonary artery pressure; MPRA: mean pressure right atrium; PVR: pulmonary vascular resistance; CI: cardiac index; S pa O 2 ,: oxygen saturation in the pulmonary artery. *N (mean ± SD); †N (%).